Literature DB >> 9747958

Elevated hepatocyte growth factor in sera from patients with insulin-dependent diabetes mellitus.

B Kulseng1, M Børset, T Espevik, A Sundan.   

Abstract

Hepatocyte growth factor (HGF) is a pleiotropic cytokine known to be involved in tissue regeneration and repair. We measured serum levels of HGF in patients with insulin-dependent diabetes mellitus (type 1). The patients were divided into four groups: (1) 10 patients at clinical presentation before insulin treatment; (2) 19 patients with newly diagnosed type 1 diabetes (diabetes duration 1/2-3 years); (3) 14 patients with long-standing type 1 diabetes without renal involvement (diabetes duration >10 years, and urinary albumin excretion (UAER) <20 microg/ min); and (4) 20 patients with long-standing type I diabetes with renal involvement (diabetes duration >10 years and UAER 20-500 microg/min). Sera from 24 age- and sex-matched healthy blood donors constituted a control group. The HGF levels of the four groups were (mean +/- SD); group 1, 0.74+/-0.14; group 2, 0.78+/-0.40; group 3, 0.86+/-0.42; group 4, 0.79+/-0.27 ng/ml, compared to 0.43+/-0.24 ng/ml in the control group (P<0.0008). HGF levels were not significantly different between the four patient groups. The elevated serum HGF levels did not correlate with complications related to type 1 diabetes, such as UAER, retinopathy and macrovascular complications, suggesting that HGF levels were not associated with the type 1 diabetes complications. In conclusion, our results show that type 1 diabetic patients have increased serum HGF levels compared with controls and that HGF is elevated to the same extent in newly diagnosed as well as in long-standing type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9747958     DOI: 10.1007/s005920050107

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  5 in total

1.  Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy.

Authors:  A Cantón; R Burgos; C Hernández; C Mateo; R M Segura; J Mesa; R Simó
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

2.  Circulating level of hepatocyte growth factor predicts incidence of type 2 diabetes mellitus: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Michael P Bancks; Suzette J Bielinski; Paul A Decker; Naomi Q Hanson; Nicholas B Larson; Hugues Sicotte; Christina L Wassel; James S Pankow
Journal:  Metabolism       Date:  2015-10-21       Impact factor: 8.694

3.  Disruption of hepatocyte growth factor/c-Met signaling enhances pancreatic beta-cell death and accelerates the onset of diabetes.

Authors:  Jose Mellado-Gil; Taylor C Rosa; Cem Demirci; Jose A Gonzalez-Pertusa; Silvia Velazquez-Garcia; Sara Ernst; Shelley Valle; Rupangi C Vasavada; Andrew F Stewart; Laura C Alonso; Adolfo Garcia-Ocaña
Journal:  Diabetes       Date:  2010-10-27       Impact factor: 9.461

4.  Early Pregnancy Maternal Hepatocyte Growth Factor and Risk of Gestational Diabetes.

Authors:  Michal Dishi; Karin Hevner; Chunfang Qiu; Neway G Fida; Dejene F Abetew; Michelle A Williams; Daniel A Enquobahrie
Journal:  Br J Med Med Res       Date:  2015-06-11

5.  Aptamer-based search for correlates of plasma and serum water T2: implications for early metabolic dysregulation and metabolic syndrome.

Authors:  Vipulkumar Patel; Alok K Dwivedi; Sneha Deodhar; Ina Mishra; David P Cistola
Journal:  Biomark Res       Date:  2018-09-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.